Tom van den Ende

Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT)

Tom van den Ende, Nicolien C. de Clercq, Mark I. van Berge Henegouwen et al. · Clinical Cancer Research · 2021 · 278 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Fecal Microbiota Transplantation from Overweight or Obese Donors in Cachectic Patients with Advanced Gastroesophageal Cancer: A Randomized, Double-blind, Placebo-Controlled, Phase II Study

Nicolien C. de Clercq, Tom van den Ende, Andrei Prodan et al. · Clinical Cancer Research · 2021 · 70 citations · Full text

Medicine, Oncology, Pharmacology +13

Estrogen-related receptor alpha drives mitochondrial biogenesis and resistance to neoadjuvant chemoradiation in esophageal cancer

Mark P.G. Dings, Amber P. van der Zalm, Sanne Bootsma et al. · Cell Reports Medicine · 2022 · 50 citations · Full text

Medicine, Cancer Biology, Oncology +17

Multi-modal cell-free DNA genomic and fragmentomic patterns enhance cancer survival and recurrence analysis

Norbert Moldován, Ymke van der Pol, Tom van den Ende et al. · Cell Reports Medicine · 2023 · 47 citations · Full text

Medicine, Molecular Biology, Oncology +17

The Efficacy and Safety of (Neo)Adjuvant Therapy for Gastric Cancer: A Network Meta-analysis

Tom van den Ende, Emil ter Veer, Mélanie Machiels et al. · Cancers · 2019 · 39 citations · Full text

Medicine, Oncology, Surgery +16